SURMODICS, INC.

Critical Limb Ischemia Market Projected to Reach $2.5 Billion by 2035, Driven by Novel Therapies and Advanced Diagnostics

8 days ago

• The critical limb ischemia (CLI) market is expected to grow from $1.4 billion in 2024 to $2.5 billion by 2035, with a CAGR of 6.66%, fueled by advances in early detection technologies and personalized medicine approaches. • Novel therapies in development include oxygen carriers (YQ23), autologous stem cell treatments (ASCT-01, CLBS12, ACP-01), and cell-based therapies (REX-001), all aimed at promoting angiogenesis and improving tissue perfusion in ischemic limbs. • The United States represents the largest CLI market, with significant growth driven by FDA regulatory support through fast-track designations and regenerative medicine advanced therapy approvals for innovative treatments.

SurVeil DCB Shows Comparable Efficacy to IN.PACT Admiral with 75% Lower Paclitaxel Dose in TRANSCEND Trial

a month ago

• The TRANSCEND trial demonstrated that Surmodics' SurVeil drug-coated balloon achieved non-inferior safety and efficacy outcomes compared to IN.PACT Admiral DCB despite using 75% less paclitaxel in patients with femoropopliteal arterial disease. • Results published in the European Journal of Vascular and Endovascular Surgery showed comparable 12-month primary patency (82.2% vs 85.9%) and primary safety endpoints (91.8% vs 89.9%) between the two devices. • The global randomized study, conducted across 65 sites in 9 countries with 446 patients, represents the first head-to-head comparison of drug-coated balloons for peripheral artery disease treatment.